



HUTCHISON CHINA MEDITECH LTD

## PRESS RELEASE

### Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM)

#### Chi-Med enters collaboration with the University of Cambridge

**London, Friday, 18 December 2009:** Chi-Med, the majority owned subsidiary of Hutchison Whampoa Limited, today announces that it, through its wholly-owned subsidiary, has entered into a collaboration agreement with the University of Cambridge to study the angiogenesis effect of various proprietary and non-proprietary substances derived from Chinese medicinal plants.

Chi-Med’s proprietary patent medicine for heart disease, Shexiang Baoxin Pill (“SXBX Pill”), which sold over 400 million doses in China in the first half of 2009, has been shown to have angiogenesis effects. The University of Cambridge will focus research on the core ingredients of the SXBX Pill and study their efficacy and mechanisms of action in modulating angiogenesis, the growth of new capillary blood vessels in the body. Angiogenesis is a physiological process for healing and reproduction, controlled by a balance of growth and inhibitory factors. Dysfunctional angiogenesis is associated with more than 80 unrelated diseases such as cancer, diabetic retinopathy, coronary artery disease and stroke.

Modulation of angiogenesis in the skin has been shown to affect skin ageing. The three-year collaboration, led by Dr. Tai-Ping Fan, of the Department of Pharmacology, University of Cambridge, will also endeavour to identify active angiogenesis modulating ingredients for skin care products to be marketed under the Sen consumer products brand.

**Ends**

#### Enquiries

**Chi-Med**

Christian Hogg, CEO

Telephone: +852 2121 8200

**Citigate Dewe Rogerson**

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

## **About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited. [www.chi-med.com](http://www.chi-med.com)

## **About the University of Cambridge**

The University of Cambridge was founded in 1209 and celebrates its 800<sup>th</sup> anniversary this year. Its mission is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. It is made up of 31 colleges and more than 100 departments that cater for some 12,000 undergraduate and 6,000 postgraduate students.

The University's reputation for outstanding academic achievement is known worldwide and reflects the intellectual achievement of its students, as well as the world-class original research carried out by the staff of the University and the Colleges.

Some of the world's most significant scientific breakthroughs have occurred at the University, including the splitting of the atom, invention of the jet engine and the discoveries of stem cells, plate tectonics, pulsars and the structure of DNA. From Isaac Newton to Stephen Hawking, the University has nurtured some of history's greatest minds and has produced more Nobel Prize winners than any other UK institution with more than 80 laureates. [www.cam.ac.uk](http://www.cam.ac.uk)